Bristol-Myers Squibb's trading volume on February 23rd was $661 million, ranking 170th among U.S. stocks on that day.

On February 23, 2026, Bristol-Myers Squibb (BMY) had a trading volume of $661 million, ranking 170th among U.S. stocks that day, with a 13.80% increase from the previous day. The trading volume was 10.8378 million shares.

Bristol-Myers Squibb (BMY) rose 0.97% on February 23, 2026, closing at $61.25. The stock increased 0.84% over the past 5 trading days, 11.26% for the entire month of February, 13.55% since the beginning of the year, and 9.71% over the past 52 weeks.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to listings less than 1 month or fewer than 5 trading days).

On February 23, 2026, Piper Sandler maintained an “Overweight” rating for Bristol-Myers Squibb with a target price of $75.

Bristol-Myers Squibb was founded in August 1933 and registered in Delaware, USA. Its origins trace back to a company established in New York in 1887, which was renamed after a merger in 1989. As a biopharmaceutical company, Bristol-Myers Squibb focuses on discovering, developing, licensing, manufacturing, marketing, and selling innovative medicines to combat serious diseases. The company’s strategic approach combines the resources and scale of large pharmaceutical firms with the agility and innovation focus of the biotech industry. Bristol-Myers Squibb prioritizes transformative drugs in oncology, hematology, immunology, cardiovascular, and neuroscience, aiming to deliver long-term value and competitive advantages. As a global research-based pharmaceutical company, Bristol-Myers Squibb’s products are sold worldwide, serving entities including wholesalers, distributors, and specialty pharmacies, with significant manufacturing operations in multiple countries.